Bimekizumab (Bimzelx®) for psoriatic arthritis. HTA ID: 23075

Assessment Status Rapid Review Complete
HTA ID 23075
Drug Bimekizumab
Brand Bimzelx®
Indication Bimekizumab (Bimzelx®) is indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs
Assessment Process
Rapid review commissioned 11/12/2023
Rapid review completed 21/12/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that bimekizumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. April 2024